Reshef A, Nissen H, Triger L, Hensen T S, Eliav O, Schurr D, Safadi R, Gare M, Leitersdorf E
Division of Medicine, Center for Research Prevention and Treatment of Atherosclerosis, Hadassah University Hospital, Jerusalem, Israel.
Hum Genet. 1996 Nov;98(5):581-6. doi: 10.1007/s004390050263.
Familial hypercholesterolemia (FH) is an autosomal dominant disease caused by a multitude of low density lipoprotein receptor (LDL-R) mutations. The purpose of the current investigation was to define the spectrum of mutations causing FH in Israel and determine their relative distribution among diverse origin groups. A total of 193 FH families were recruited in Israel, 54 of them through the MED PED (Make Early Diagnosis Prevent Early Death) FH program. Molecular analysis of the LDL-R using single-strand conformation polymorphism (SSCP) or denaturing gradient gel electrophoresis (DGGE) or both has been completed in 95 index cases. This analysis resulted in the identification of 15 LDL receptor mutations, including 7 novel mutations (del 197, C308G, R385W, splice junction mutation of intron 14, del 328, del 502-505, stop 10, del 165), that were present in 49 index cases (52%). The 15 mutations are mapped to three known functional domains of the receptor (7 in the LDL-binding region, 7 in the epidermal growth factor precursor homology region and 1 in the membrane-spanning region). Screening for the identified mutations in the remaining 98 index cases enabled the molecular diagnosis of 31 additional cases. It is therefore concluded that 80 out of 193 index cases (41%) harbor 1 of the 15 mutations described here. Three mutations-del197 (FH-Lithuania), D147H (FH-Sephardic), and stop660 (Lebanese allele)-were found in a total of 66 index cases (34%); these may be regarded as founder mutations in the three respective origin groups. In conclusion, in Israel molecular heterogeneity at the LDL receptor gene locus reflects the ethnic distribution of its origin groups. The results of the present investigation provide valuable diagnostic tools for a subset of the Israeli patients with FH who are at high risk for atherosclerosis and its complications.
家族性高胆固醇血症(FH)是一种常染色体显性疾病,由多种低密度脂蛋白受体(LDL-R)突变引起。本研究的目的是确定以色列导致FH的突变谱,并确定它们在不同起源群体中的相对分布。在以色列共招募了193个FH家庭,其中54个是通过MED PED(早诊断预防早死亡)FH项目招募的。对95例先证者完成了使用单链构象多态性(SSCP)或变性梯度凝胶电泳(DGGE)或两者对LDL-R进行的分子分析。该分析导致鉴定出15种LDL受体突变,包括7种新突变(del 197、C308G、R385W、内含子14剪接连接突变、del 328、del 502 - 505、stop 10、del 165),这些突变存在于49例先证者中(52%)。这15种突变定位于受体的三个已知功能域(7种在LDL结合区域,7种在表皮生长因子前体同源区域,1种在跨膜区域)。对其余98例先证者进行已鉴定突变的筛查,又使另外31例得以进行分子诊断。因此得出结论,193例先证者中有80例(41%)携带此处描述的15种突变中的一种。在总共66例先证者(34%)中发现了三种突变——del197(FH - 立陶宛)、D147H(FH - 西班牙裔)和stop660(黎巴嫩等位基因);这些可被视为三个各自起源群体中的奠基者突变。总之,在以色列,LDL受体基因位点的分子异质性反映了其起源群体的种族分布。本研究结果为一部分有动脉粥样硬化及其并发症高风险的以色列FH患者提供了有价值的诊断工具。